Transgene: gains ground on preclinical study

(CercleFinance.com) - Transgene shares rallied on Tuesday morning following the publication of positive preclinical data on its oncolytic virus for the treatment of tumors.


At around 11:00 a.m., the biotech company's shares soared by almost 12%, marking one of the biggest gains on the Paris market, with volumes already 30 times their daily average of recent sessions.

These results, published in the Journal for ImmunoTherapy of Cancer (JITC), demonstrate that TG6050 induced a reduction in tumor size and a profound remodeling of the tumor microenvironment.

Beyond the transformation of the tumor immune microenvironment in animal models, sustained intratumoral expression of interleukin-12 (IL-12) and anti-CTLA-4 antibody at high concentrations, with no observed systemic toxicity, was also reported.

These preclinical data demonstrate the ability of our invir.IO oncolytic virus platform to generate promising candidates, and support our decision to pursue the clinical development of TG6050 in metastatic non-small cell lung cancer", commented Dr. Maud Brandely, Transgene's Chief Medical Officer (CMO).

TG6050, an oncolytic virus armed with interleukin 12 (IL-12) and an anti-CTLA4 antibody, is currently in a Phase I clinical trial in lung cancer.

Despite this good news, the share price is still down 15% year-to-date.

Copyright (c) 2024 CercleFinance.com. All rights reserved.